EcoR1 Capital’s Nurix Therapeutics NRIX Stock Holding History

EcoR1 Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.55M	Buy	+270,000	New	+$4.6M	0.32%	26
2022 Q2	–	Sell	-254,473	Closed	-$3.56M	–	88
2022 Q1	$3.56M	Sell	254,473 -55,067	-18%	-$977K	0.11%	58
2021 Q4	$8.96M	Sell	309,540 -817,100	-73%	-$24.8M	0.29%	40
2021 Q3	$33.8M	Sell	1,126,640 -841,310	-43%	-$26M	1.17%	17
2021 Q2	$52.2M	Sell	1,967,950 -51,069	-3%	-$1.5M	1.95%	14
2021 Q1	$62.8M	Buy	2,019,019 +475,000	+31%	+$18M	2.78%	12
2020 Q4	$50.8M	Buy	1,544,019 +351,863	+30%	+$11.7M	2.73%	15
2020 Q3	$41.6M	Buy	+1,192,156	New	+$30M	2.97%	13

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital's NRIX Position: Q2 2026 in Review

EcoR1 Capital opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 270,000 shares worth $6.55M. The stake represents 0.32% of the portfolio and ranks #26 among its holdings. This is a return to the name: EcoR1 Capital previously reported a position in NRIX as recently as Q1 2022.

EcoR1 Capital first reported a position in NRIX in Q3 2020 and has held it in 8 quarters since. The position peaked at $62.8M in Q1 2021. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

EcoR1 Capital held 270,000 shares of Nurix Therapeutics worth $6.55M as of Q2 2026.
Nurix Therapeutics was a new EcoR1 Capital position in Q2 2026.
Nurix Therapeutics made up 0.32% of EcoR1 Capital's portfolio in Q2 2026, its #26 holding.
EcoR1 Capital first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 8 quarters since.
EcoR1 Capital's Nurix Therapeutics position peaked at $62.8M in Q1 2021.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.